Free Trial
NASDAQ:IBRX

ImmunityBio Q2 2024 Earnings Report

ImmunityBio logo
$2.37 -0.01 (-0.42%)
Closing price 09/3/2025 04:00 PM Eastern
Extended Trading
$2.38 +0.01 (+0.63%)
As of 09/3/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ImmunityBio EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.17
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

ImmunityBio Revenue Results

Actual Revenue
$1.05 million
Expected Revenue
$2.53 million
Beat/Miss
Missed by -$1.48 million
YoY Revenue Growth
N/A

ImmunityBio Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Sunday, August 11, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

ImmunityBio's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

ImmunityBio Earnings Headlines

Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...tc pixel
ImmunityBio announces Anktiva trial
See More ImmunityBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImmunityBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmunityBio and other key companies, straight to your email.

About ImmunityBio

ImmunityBio (NASDAQ:IBRX) is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity. Anktiva is being evaluated in combination with tumor-targeting monoclonal antibodies and immune checkpoint inhibitors for treatment of non–muscle-invasive bladder cancer as well as other solid tumors. In parallel, ImmunityBio is advancing novel T cell receptor (TCR) therapies and off-the-shelf NK cell products aimed at solid and hematologic malignancies.

Beyond oncology, the company has pursued viral-vectored vaccine candidates for infectious diseases, including a Phase 1 program for COVID-19. These efforts leverage a proprietary human adenovirus (hAd5) backbone intended to elicit robust cellular and humoral immune responses. ImmunityBio’s integrated approach combines cell engineering, cytokine biology and vaccine technology to build a diversified pipeline across multiple therapeutic areas.

Founded as NantKwest and rebranded to ImmunityBio in 2020, the company operates under the leadership of CEO Tarek Tantawi and was co-founded by biotech entrepreneur Dr. Patrick Soon-Shiong. Headquartered in Culver City, California, ImmunityBio conducts preclinical research and clinical trials in North America, Europe and Australia. The company maintains collaborations with academic institutions, government agencies and industry partners to accelerate development and regulatory filings for its immunotherapy candidates.

View ImmunityBio Profile

More Earnings Resources from MarketBeat